Renin-Angiotensin System Inhibitors, Type 2 Diabetes and Fibrosis Progression: An Observational Study in Patients with Nonalcoholic Fatty Liver Disease.
Serena PelusiSalvatore PettaChiara RossoVittorio BorroniAnna Ludovica FracanzaniPaola DongiovanniAntonio CraxiElisabetta BugianesiSilvia FargionLuca Vittorio ValentiPublished in: PloS one (2016)
NASH is not required for fibrosis progression in NAFLD, whereas T2D seems to drive fibrogenesis independently of hepatic inflammation. Use of RAS inhibitors may contrast fibrosis progression especially in high-risk patients affected by T2D.